GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Lecanemab Real-World Safety: Duke Health Study Insights for Alzheimer’s Patients
For decades, the search for a way to slow down Alzheimer’s disease felt like chasing a horizon that never got closer. However, the arrival of anti-amyloid therapies like lecanemab has shifted the conversation from "what if" to "how." While clinical trials provide a controlled environment to test these drugs
Tiny Bubbles, Big Breakthrough: How Exosomes Carry Alzheimer's Treatments Past the Blood–Brain Barrier
Your brain consumes roughly 20% of your body's energy, meaning it relies on a massive network of blood vessels. To protect your central nervous system from harmful chemical swings and infections, the cells lining these blood vessels fit together like microscopic puzzle pieces sealed with airtight biological glue. This tight network is the Blood–Brain Barrier.
Alzheimer’s & the GRK2 Enzyme: A Sleeping Key to Brain Energy
Discover how ETH Zurich researchers uncovered GRK2 enzyme aggregates as a novel Alzheimer's target, offering new hope for energy-restoring therapies.
A New Era in Alzheimer's Research: Moving Beyond Amyloid
For decades, the public conversation surrounding Alzheimer’s disease focused almost exclusively on a single culprit: sticky protein deposits in the brain known as amyloid-beta plaques. The dominant theory held that if medicine could simply scrub these plaques away, memory loss and cognitive decline could be halted.
Beyond Memory Loss: MRI Early Detection & 2026 Alzheimer's Advances
Groundbreaking 2026 research reveals structural brain changes precede amyloid plaques by 7+ years, transforming early detection, atypical Alzheimer's care, and targeted treatments.
The Alzheimer’s Revolution: Simple Blood Tests Spotting Risk Years Before Symptoms
For decades, Alzheimer’s disease has been a silent and elusive adversary. It crawls slowly through the brain, dismantling neural connections and building up toxic protein barriers long before the first lapse in memory occurs. Traditionally, confirming a diagnosis of Alzheimer’s has been a reactive process. Patients and their families had to wait for undeniable symptoms—confusion, forgetfulness, and changes in behavior—before seeking medical confirmation. By the time these symptoms manifest, significant and often irreversible brain damage has already occurred.
AI Brain Map Predicts Early-Onset Alzheimer's Progression
When most people picture Alzheimer's disease, they imagine an individual in their late 70s or 80s gradually experiencing memory loss. However, Early-Onset Alzheimer's Disease (EOAD) paints a starkly different, often heartbreaking picture. Striking individuals under the age of 65—frequently in their 40s or 50s—EOAD attacks people who are at the very peak of their personal and professional lives.
Dementia Risk After 90: New Study Shows Why We're Never In the Clear
It is a common and comforting assumption: if you or your loved ones can make it to 90 years old with a sharp mind, you have somehow beaten the odds. We tend to think that after a certain milestone, the risk of cognitive decline plateaus, and we can finally breathe a sigh of relief.
Estrogen Receptor ERβ: A New Hope in the Fight Against Alzheimer’s in Women
If you look at the statistics for Alzheimer’s disease, one striking detail immediately stands out: almost two-thirds of all people living with Alzheimer's are women. For decades, scientists and doctors explained this gap simply by pointing to the calendar—women
Optimizing FDA Diversity Action Plan Compliance and Alzheimer’s Clinical Trial Matching Through Agentic AI
Discover how Glassbury AI leverages agentic NLP, SMART on FHIR protocols, and trust-centric community frameworks to solve Alzheimer's trial enrollment bottlenecks, de-risk asset beta, and automate FDA Diversity Action Plan (DAP) compliance under FDORA.
"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded
If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.
Inside the Brain's Folding Architecture: How 3D Genome Structure Holds the Key to Alzheimer's
Learn how 3D genome folding in neurons impacts Alzheimer's disease. Discover the University of Pittsburgh's breakthrough research on chromatin remodelers and brain cell architecture.
The 158-Trial Revolution: Inside the Landmark World Alzheimer Report 2026
For decades, medicine treated dementia as an unyielding natural consequence of aging. But between the massive trial pipeline data released this week, new lipid discoveries from UT Health, and a surge in repurposing existing cardiovascular medications, the paradigm has officially shifted from late-stage symptom management to early multi-target prevention.
Unlocking Clinical Equity: How Glassbury AI Meets FDA Diversity Action Plan Mandates in Alzheimer’s Research
Explore how Glassbury AI uses Google Cloud, MedGemma, and Vertex AI Explainable AI to guarantee FDA Diversity Action Plan compliance and accelerate Alzheimer's clinical trial matching.
The Role of AI in Therapeutic Drug Research and Development: Benefits and Challenges
Artificial intelligence (AI) has emerged as a transformative technology across various sectors, and its potential impact on therapeutic drug research and development is significant. By leveraging AI algorithms and machine learning, researchers can potentially accelerate the drug discovery process, identify promising drug candidates, and optimize treatment strategies. However, the integration of AI
A Legacy of Mistrust: Understanding and Addressing Vaccine Hesitancy Among People of Color
The recent COVID-19 pandemic has laid bare a stark reality: people of color (POC) are disproportionately hesitant to engage with medical and governmental institutions, particularly regarding vaccinations. This hesitancy, often labeled as "vaccine hesitancy," is not simply a matter of ignorance or fear. It is rooted in a deeply ingrained distrust that stems from a long history of systemic racism and medical discrimination.
The Future of Drug Research Privacy: Navigating Evolving Regulations
Drug research is a critical endeavor that pushes the boundaries of medical science, leading to the development of life-saving treatments and therapies. However, this vital process involves collecting and analyzing sensitive personal data from research participants, raising important ethical and privacy concerns. As technology advances and data collection methods become more sophisticated, the need for robust privacy regulations in drug research is more pressing than ever.
The Regulatory Shift: From Optional Inclusion to Mandatory Action
Learn how Glassbury AI bridges grassroots engagement and LLM companions to meet FDA Diversity Action Plan compliance and solve Alzheimer's trial enrollment.
The Hurdles in the Path to Cures: The Unique Challenges of Rare Disease Research
Rare diseases, despite affecting millions of people worldwide, often exist in a shadow cast by more prevalent illnesses. Their rarity presents a unique set of challenges for researchers striving to develop effective treatments and cures. From limited funding to small patient populations, the path to conquering rare diseases is fraught with obstacles.
The Ripple Effect of Altruism: Why Unconditional Love Matters
In today's fast-paced, self-centered world, it's easy to get caught up in the pursuit of personal gain and happiness. We are constantly bombarded with messages promoting individual success and the accumulation of wealth and possessions. However, amidst this relentless focus on self, there's a growing recognition of the transformative power of altruism – the selfless act of caring for others without expecting anything in return. In this blog post, we will explore the profound impact of altruistic love and why it is essential for building a more compassionate and fulfilling world.